Cetuximab biosimilar (Celltrion)

西妥昔单抗生物类似药 (Celltrion)

Report date: 2025/05/06 15:48:42

Base Information

Drug NameCetuximab biosimilar (Celltrion)
Drug Alias NameCT-P15
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCelltrion Healthcare Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A